Research*EU Magazine | Number 36 (October 2014)

Biotech for longer, healthier lives

Summary:

Some 50 % of all new medicines originate from biotechnologies, benefiting 350 million patients in Europe, and this proportion is growing each year. The sector is also an important factor for growth, and public funding is essential to boost innovation. It is therefore only natural that the EU’s Seventh Framework Programme for Research (FP7) strongly supports medical biotechnology, with a large number of FP7 projects dedicated to four domains: high-throughput research; detection, diagnosis and monitoring; prediction of suitability, safety and efficacy of therapies; and innovative therapeutic approaches and intervention.

This edition of the Research*EU magazine puts the spotlight on some of these projects, either completed over the last year or being close to completion. These special sections include an interview with Dr David Sassoon, coordinator of ENDOSTEM, a project looking into ways to boost regeneration mechanisms for patients with degenerative muscular disease.

Our nine ‘specials’ are followed by our usual seven sections on biology and medicine, social sciences and humanities, energy and transport, the environment, IT and telecommunications, industrial technologies and space. The magazine closes with a list of upcoming events.

Contents:

Health

Industrial Technologies

Climate Change and Environment

Digital Economy

Energy

• Primary Source

• Alternative Source